Kodiak Sciences Valuation

Is KOD * undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

Below Fair Value
Significantly Below Fair Value
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of KOD * when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate KOD *'s fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate KOD *'s fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for KOD *?

Other financial metrics that can be useful for relative valuation.

The above table shows the n/a ratio for KOD *. This is calculated by dividing KOD *'s market cap by their current preferred multiple.
What is KOD *'s n/a Ratio?
n/a	0x
n/a	n/a
Market Cap	US$238.97m

KOD * key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	n/a
Enterprise Value/EBITDA	n/a
PEG Ratio	n/a

Price to Book Ratio vs Peers

How does KOD *'s PB Ratio compare to its peers?

The above table shows the PB ratio for KOD * vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PB	Estimated Growth	Market Cap
Peer Average	2.4x
LAB B Genomma Lab Internacional. de	2x	18.5%	Mex$21.2b
ENTA Enanta Pharmaceuticals	1.4x	-0.8%	US$221.8m
GNFT Genfit	2.6x	33.8%	€257.5m
1541 ImmuneOnco Biopharmaceuticals (Shanghai)	3.4x	n/a	HK$2.3b
KOD * Kodiak Sciences	0.5x	29.5%	Mex$239.0m

Price-To-Book vs Peers: KOD * is good value based on its Price-To-Book Ratio (0.5x) compared to the peer average (1.8x).

Price to Earnings Ratio vs Industry

How does KOD *'s PE Ratio compare vs other companies in the Global Biotechs Industry?

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	0%
	n/a	n/a	n/a

Fetching data

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	0%
	n/a	n/a	n/a

No more companies

Price-To-Book vs Industry: KOD * is good value based on its Price-To-Book Ratio (0.5x) compared to the Global Biotechs industry average (2.2x).

Price to Book Ratio vs Fair Ratio

What is KOD *'s PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

KOD * PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio	0.5x
Fair PB Ratio	n/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate KOD *'s Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.